Home > others & > Silibinin

Silibinin

水飞蓟宾,Silybin

Silibinin为抗癌和化疗预防化合物，能抑制细胞增殖和迁移。

目录号
EY0342
EY0342
EY0342
EY0342
纯度
99.53%
99.53%
99.53%
99.53%
规格
5 mg
10 mg
25 mg
50 mg
原价
840
1200
2500
3900
售价
840
1200
2500
3900
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Silibinin, the main flavonoid extracted from the milk thistle Silybum marianum, displays hepatoprotective properties in acute and chronic liver injury.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Al-Anati L, et al. Mol Nutr Food Res, 2009, 53(4), 460-466.
    [2] Chapla Agarwal et. Al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene, 22(51), 8271-8282 (2003).
    [3] Anil K Tyagi et. Al. Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochemical and Biophysical Research Communications, 312(4), 1178-1184 (2003).
    [4] Lin Qi et. Al. Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biology & Therapy, 2(5), 526-531 (2003).

    分子式
    C25H22O10    		 分子量
    482.44    		 CAS号
    22888-70-6    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    ≥10 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT00487721 Prostate Cancer Drug: Silibin-Phytosome University of Colorado, Denver|Sir Mortimer B. Davis - Jewish General Hospital Phase 2 2006-08-01 2014-03-03
    NCT00684268 Hepatitis C Drug: Silibinin|Drug: Silibinin Medical University of Vienna Phase 2 2007-10-01 2012-10-24
    NCT00915681 Amatoxin Poisoning|Amanita Poisoning|Mushroom Poisoning|Liver Failure Drug: Silibinin Madaus Inc Phase 2|Phase 3 2010-02-01 2016-03-18
    NCT01816490 HIV|Hepatitis C Drug: Intravenous Silibinin (iSIL) University of Zurich Phase 2 2013-04-01 2015-03-04
    NCT01871662 Hepatitis C, Chronic Drug: Legalon庐 SIL (Silibinin)|Drug: Pegylated interferon alfa2b|Drug: Ribavirin Rottapharm Phase 2|Phase 3 2013-08-01 2015-03-04
    NCT02146118 Carcinoma, Non-Small-Cell Lung Drug: Erlotinib|Dietary Supplement: Silybin-phytosome MedicalLogic|Kosin University Gospel Hospital Phase 2 2014-04-01 2014-05-20
    NCT01957319 Work Ability|Depression Drug: Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|Drug: sugar pill University of Catania Phase 3 2010-02-01 2013-09-30
    NCT01535092 HCV Recurrence After Liver Transplantation Drug: Silibinin|Drug: Placebo Rottapharm Phase 2 2010-09-01 2012-02-14
    NCT01935817 Liver Fibrosis Drug: Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|Drug: Placebo University of Catania Phase 3 2010-06-01 2013-09-04
    NCT01518933 Hepatitis C Virus Recurrence Drug: Silibinin (Legalon-SIL)|Drug: Saline Rottapharm|Azienda Ospedaliera Universitaria Policlinico Phase 2 2011-08-01 2015-03-04
    NCT02633696 Healthy Volunteers Drug: silybin phosphatidylcholine|Drug: Legal贸n SIL Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Fundaci贸n Mutua Madrile帽a Phase 1 2013-10-01 2016-07-08
    NCT00915200 Diabetic Nephropathies|Proteinuria|Oxidative Stress Dietary Supplement: N-acetylcysteine|Dietary Supplement: silibin|Dietary Supplement: high-dose silibin|Dietary Supplement: N-acetylcysteine placebo|Dietary Supplement: silibin placebo The University of Texas Health Science Center at San Antonio|National Center for Complementary and Integrative Health (NCCIH)|VA Office of Research and Development Phase 2 2009-10-01 2016-06-23
    NCT01129570 Advanced Hepatocellular Carcinoma Drug: Silybin Abby Siegel|Lotte & John Hecht Memorial Foundation|Columbia University Phase 1 2010-02-01 2013-11-21
    NCT02534129 Radiodermatitis Drug: Difinsa53|Drug: Aquaphor ProTechSure Scientific, Inc.|Poudre Valley Health System Phase 1|Phase 2 2015-08-01 2016-07-19
    NCT01265563 Diabetic Nephropathy|Proteinuria|Oxidative Stress Drug: N-acetylcysteine placebo + silibin placebo|Drug: N-acetylcysteine active + silibin placebo|Drug: N-acetylcysteine placebo + silibin active|Drug: N-acetylcysteine active + silibin active|Drug: N-acetylcysteine active + high-dose silibin active VA Office of Research and Development|National Center for Complementary and Integrative Health (NCCIH) Phase 2 2011-01-01 2016-04-18
    NCT00181662 Healthy Drug: Curcumin Massachusetts General Hospital 2005-08-01 2007-04-02
    NCT01003236 Diabetic Nephropathy Drug: placebo|Drug: Milk Thistle extract Shiraz University of Medical Sciences Phase 2 2010-10-01 2012-06-21
    NCT02529605 Healthy Dietary Supplement: Product B庐 IsaGenesis庐|Dietary Supplement: IsaGenesis庐 University of Florida|Isagenix International LLC 2015-09-01 2016-11-30
    NCT01049178 Atopic Asthma Drug: Oral Silymarin|Drug: Oral Silymarin, maintenance dose|Drug: Placebo Vanderbilt University Phase 2|Phase 3 2010-09-01 2014-02-20
    NCT02006498 Non-alcoholic Fatty Liver Disease Drug: Sillymarin|Drug: Placebo University of Malaya|Rottapharm Phase 2 2012-06-01 2016-01-06
    NCT00055445 Hepatitis C, Chronic Drug: IdB 1016 National Center for Complementary and Integrative Health (NCCIH) Phase 1|Phase 2 2003-11-01 2006-08-17
    NCT02961413 Drug Induced Liver Disease Study Group All 10000 2017-07-01 2016-11-01

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：